novo norkdisk R&D Pipeline
zhion@zhion.com                 November 30, 2005
PHARMCEUTICAL
INDUSTRY

Foundamental
Science
Colloidal
Stabilization

Drug Product
Development
Patent Application
Product
Development
Product
Ingredients
Colorant
Scale up a batch 1
Drug Delivery
Industry
Drug Delivery -
Smart Bomb
Lotion, Cream,
Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR
Coating-Aquacoat

Drug Industry
Drug
Competitions
Drug in
Development
Cholesterol-lowering
Drug-Terminologies
Packaging
Materials

Market
Drug Dev- 2004
Drug Dev -
2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market

Novo Norkdisk
R&D

Equipment
Blenders

CONTRACT
MANUFACT.
Nutrition
Supplements

NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Erbitux
(cetuximab)
Gardasil
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm
(Lidocaine)
Liraglutide
Lyrica (pregabalin)
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug
Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2

Double-blind
Study
Novo Nordisk
Novo Nordisk was created in 1989 through a merger between two
Danish companies: Novo Industri A/S and Nordisk Gentofte A/S. In
1941, Novo launches its first enzyme, trypsin, extracted from the
pancreas of animals and used for bating leather before tanning. In 1946,
Nordisk develops Isophane insulin (NPH), a neutral insulin with
prolonged action. In 1947 Novo Norkdisk luanched its first
fermentation product Penicillin Novo. In 1953, Nova Nordisk lauched
Lente - a long-acting insulin suspension. In 1973, Novo Norkdisk
marketed Nanormon growth hormone for the treatment of growth
hormone insufficiency. It also introduced Monocomponent (MC) insulin.
In 1982, Novo Norkdisk launched human monocomponent insulin - the
first insulin preparation idential to human insulin. It is extracted from the
pancreas of pigs and converted to human insulin. In the last two
decades, they developed and launched various products including
NovoPen (an injection system, Norditropin (genetically engineered
human growth hormone),  NovoLet (prefilled insulin syringe),
NovoSeven (treatment of haemophilia), NovoNorm/Prandin (oral
treatment for type 2 diabetes), Activelle (combined oral HRT), Innovo
(insulin doser), NovoRapid (rapid-acting insulin analogue), Norditropin,
Simplexx (pen system for liquid growth hormone), Novofem (a low-
dose sequential combined oral HRT), InnoLet (insulin delivery system
for users with poor eyesight, InDuo (combined blood glucose monitor
and insulin injection system), and a few more products.

Today, Novo Nordisk has the broadest diabetes product portfolio in the
industry. They also have a leading position in areas such as haemostasis
management, growth disorders and hormone replacement therapy.

Compound/indication                                      Stage

NovoMix� 50 and 70                                       Submitted
Type 1 and 2 diabetes

Vagifem�                                                           Phase 3
Hormone replacement therapy

Levemir� (Insulin detemir)                             Phase 3
Type 1 and 2 diabetes

NovoSeven�, Line extension: Trauma         Phase 3     
Bleeding in emergencies, Trauma

NovoSeven�, Line extension:                         Phase 3
Intra-cerebral haemorrhages
Bleeding in emergencies,
Intra-cerebral haemorrhages

Activelle�                                                             Phase 3
Hormone replacement therapy

AERx� iDMS                                                        Phase 2
Type 1 and 2 diabetes

NovoSeven�                                                         Phase 2
Elective Surgery, Cardiac Surgery

NovoSeven�                                                         Phase 2
Bleeding in emergencies, Traumatic brain injury

NovoSeven�                                                        Phase 2
Spinal surgery

NovoSeven�                                                         Phase 2
Line extension: Variceal bleedings
Bleeding in emergencies,
Upper gastrointestinal bleeds, cirrhotic patients

Liraglutide (NN2211)                                           Phase 2
Type 2 diabetes

IL-21                                                                     Phase 1/2
Malignant melanoma, Cancer

rFXIII, Cardiac surgery                                        Phase 1
Elective Surgery, Cardiac Surgery

NN344                                                                     Phase 1
Type 1 and 2 diabetes

                                       HOME

THIS ARTICLE IS FOR YOUR REFERENCE ONLY. PUBLISHER
DOES NOT GUARANTEE ITS ACCURACY.  SOME
INFORMATION MAY ALSO BE OUTOFDATED. SOURCE
NOVO NORDISK ONLINE PUBLICATIONS NOVEMBER 30
2005